'Rare' uptick in pharma's corporate reputation

The corporate reputation of pharma according to rare disease patient groups has risen to levels not seen for five years with Roche taking the top spot for Big Pharma companies followed by Boehringer Ingelheim in second place and AstraZeneca and Sanofi tying for bronze.

The assessment came from patient groups who had worked with 14 Big Pharma companies, but when 33 companies were assessed, Sobi claimed the number one ranking, with Roche slipping to second place and Boehringer, third, according to the latest PatientView report.

Sobi has already bested Roche before, taking the number one spot according to bleeding disorder patient groups.